MedTech Dive April 22, 2024
Lumicell developed the technology to help physicians detect residual cancer in the breast cavity after surgery.
Dive Brief:
- The Food and Drug Administration approved Lumicell’s breast cancer imaging tool, the company said Thursday.
- Lumicell developed the Lumisystem imaging technology to enable surgeons to detect residual cancer in the breast cavity after performing a lumpectomy to remove the tumor.
- An FDA advisory committee voted in March that the benefits of Lumisystem outweigh the risks, with one expert predicting the system will have the biggest impact on surgeons who have higher re-excision rates.
Dive Insight:
Lumisystem has two components called Lumisight and Lumicell DVS. Lumisight is a molecule that reacts to enzymes found at higher levels in and near tumor...
Today's Sponsors
Today's Sponsor